Abstract
In the originally published version of this article, in Table 4, Ocrelizumab was incorrectly referred to as an anti-CD25 antibody. This has been corrected in the HTML and PDF versions of the article to an anti-CD20 antibody.
Original language | English |
---|---|
Article number | 49 |
Journal | Nature Reviews Disease Primers |
Volume | 4 |
Issue number | 1 |
DOIs |
|
Publication status | Published - Dec 1 2018 |
ASJC Scopus subject areas
- Medicine(all)